How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/abbv-706.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

ABBV-706 — Competitive Intelligence Brief

ABBV-706 (ABBV-706) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CSF1R inhibitor. Area: Oncology.

phase 3 CSF1R inhibitor CSF1R (Colony-Stimulating Factor 1 Receptor) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

ABBV-706 (ABBV-706) — AbbVie. ABBV-706 is a selective inhibitor of colony-stimulating factor 1 receptor (CSF1R) that reduces macrophage proliferation and activation in the tumor microenvironment.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
ABBV-706 TARGET	ABBV-706	AbbVie	phase 3	CSF1R inhibitor	CSF1R (Colony-Stimulating Factor 1 Receptor)
IMP4927	IMP4927	Impact Therapeutics, Inc.	phase 3	CSF1R inhibitor	CSF1R (Colony-Stimulating Factor 1 Receptor)
CCI18781	CCI18781	GlaxoSmithKline	phase 3	CSF1R inhibitor	CSF1R (Colony-Stimulating Factor 1 Receptor)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CSF1R inhibitor class)

AbbVie · 1 drug in this class
GlaxoSmithKline · 1 drug in this class
Impact Therapeutics, Inc. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ABBV-706 — Competitive Intelligence Brief. https://druglandscape.com/ci/abbv-706. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab